CD152 (CTLA-4) Determines CD4 T Cell Migration In Vitro and In Vivo by Knieke, Karin et al.
CD152 (CTLA-4) Determines CD4 T Cell Migration In Vitro
and In Vivo
Karin Knieke
1,2, Holger Hoff
2, Frank Maszyna
2, Paula Kolar
2, Arnhild Schrage
2, Alf Hamann
2, Gudrun F.
Debes
3, Monika C. Brunner-Weinzierl
1,2*
1Experimentelle Pa ¨diatrie, Universita ¨tskinderklinik – Otto-von-Guericke Universita ¨t, Magdeburg, Germany, 2Deutsches Rheuma-Forschungszentrum Berlin and
Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinischer Immunologie, CCM, Charite ´ -Universita ¨tsmedizin Berlin, Berlin, Germany, 3Department of
Pathobiology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
Abstract
Background: Migration of antigen-experienced T cells to secondary lymphoid organs and the site of antigenic-challenge is a
mandatory prerequisite for the precise functioning of adaptive immune responses. The surface molecule CD152 (CTLA-4) is
mostly considered as a negative regulator of T cell activation during immune responses. It is currently unknown whether
CD152 can also influence chemokine-driven T cell migration.
Methodology/Principal Findings: We analyzed the consequences of CD152 signaling on Th cell migration using chemotaxis
assays in vitro and radioactive cell tracking in vivo. We show here that the genetic and serological inactivation of CD152 in
Th1 cells reduced migration towards CCL4, CXCL12 and CCL19, but not CXCL9, in a G-protein dependent manner. In
addition, retroviral transduction of CD152 cDNA into CD152 negative cells restored Th1 cell migration. Crosslinking of
CD152 together with CD3 and CD28 stimulation on activated Th1 cells increased expression of the chemokine receptors
CCR5 and CCR7, which in turn enhanced cell migration. Using sensitive liposome technology, we show that mature
dendritic cells but not activated B cells were potent at inducing surface CD152 expression and the CD152-mediated
migration-enhancing signals. Importantly, migration of CD152 positive Th1 lymphocytes in in vivo experiments increased
more than 200% as compared to CD152 negative counterparts showing that indeed CD152 orchestrates specific migration
of selected Th1 cells to sites of inflammation and antigenic challenge in vivo.
Conclusions/Significance: We show here, that CD152 signaling does not just silence cells, but selects individual ones for
migration. This novel activity of CD152 adds to the already significant role of CD152 in controlling peripheral immune
responses by allowing T cells to localize correctly during infection. It also suggests that interference with CD152 signaling
provides a tool for altering the cellular composition at sites of inflammation and antigenic challenge.
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Introduction
The positioning of differentiated effector/memory T cells within
tissues is important for the adaptive immune responses to ensure
protection against reinfection. Chemokines and their receptors are
essential for homing of antigen-experienced T cells to lymphoid
and non-lymphoid destinations [1,2]. The signals responsible for
the chemokine-directed migration of certain T cell subsets remain
poorly characterized.
Following initial activation, naı ¨ve CD4
+ T cells can differentiate
into Th1 cells that secrete pro-inflammatory cytokines such as IFN-
c and TNFa, and induce cell-mediated immune responses [3]. Th1
responses are critical for the eradication of intracellular pathogens
such as Leishmania major and Listeria monocytogenes. However, Th1
responses also drive chronic inflammation and tissue destruction in
autoimmune diseases such as multiple sclerosis, type I diabetes,
Crohn’s disease, and rheumatoid arthritis [4–8]. Given the
requirement for trafficking of effector T cells to diverse tissue sites
in the body, it seems likely that there is substantial heterogeneity in
the migratory capacity of Th cell subsets.
CD28 and CD152 are the primary co-receptors on T cells that
mediate positive and negative costimulation using the same ligands
on APCs, CD80 and CD86. Triggering of CD28 strongly up-
regulates IL-2 production and T cell proliferation, which is
counter-regulated by CD152-mediated inhibition of IL-2 tran-
scription and cell cycle progression [9]. CD152 does not only
oppose CD28-mediated effects, but can also synergize with it, e.g.
by enhancing resistance to apoptosis [10–13]. Thus, the role of
CD152 is more complex than its traditional view as a major down-
regulator of immune responses [9,14,15]. CD152 is inducible after
stimulation of T cells and reaches maximal surface levels 48 h after
T cell stimulation [16], when maximal CD152 function is
observed. The regulation of CD152 surface expression represents
a major control point for its function because only cell surface
expressed CD152 is functional [11,16], and only a restricted
number of activated T cells can express CD152. CD152 is
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it is expressed in a polarized manner at the immunological synapse
[17]. The surface expression is mainly induced by TCR signaling
strength, but can be enhanced by soluble factors [18,19].
Costimulation is an important control point to ensure that
professional APCs define initiation, differentiation, and persistence
of T cell responses. It has recently been proposed that tissue
specific APCs direct and reprogram T cell migration into specific
tissues [20,21]. Given the central role of costimulation in
differentiation and function of T cells, we postulate that
costimulatory molecules participate in the localization of adaptive
immune responses by licensing T lymphocytes for chemotaxis. In
the present study, we investigated the functional role of CD152 in
migration of Th1 cells. We show that CD152 surface expression is
induced in Th1 cells stimulated primarily by mature DCs when
compared with other APCs. Surprisingly, CD152 engagement
induced activated Th1 cell migration towards CXCL12, CCL19,
and CCL4, the ligands for CXCR4, CCR7, and CCR5,
respectively, whereas inhibition of CD152 abrogated migration.
Importantly, CXCR4 and CCR5 and their ligands are associated
with inflammatory diseases [22,23] and CCL19 as well as
CXCL12 are also important for lymphocyte homing to lymph
nodes and Peyer’s patches [24–26]. Moreover, we show that
CD152-mediated signals endow effector T cells with the capacity
to migrate to sites of inflammation and lymph nodes. This novel
function of CD152 could explain the retention and directed
migration of effector cells to secondary lymphoid organs and sites
of antigenic-challenge and might be important for T cell
homeostasis as well as Th1-dominated diseases.
Results
Serological and genetic inactivation of CD152 reduces
chemotaxis of Th1 cells to CXCL12 and CCL4
To examine the role of CD152 in T cell migration, we
stimulated CD152-deficient (CD152
2/2) monoclonal OVA-spe-
cific TCR
tg CD4
+ T cells from OTII mice (TCR
tgCD152
2/2) and
monoclonal OVA-specific TCR
tg CD4
+ T cells from CD152
+/+
OTII mice (TCR
tgCD152
+/+) with cognate antigen in vitro and
tested chemotaxis to the CXCR4 ligand CXCL12, the CCR7
ligand CCL19, and the CCR5 ligand CCL4 in a Transwell
chemotaxis assay (Fig. 1A, and data not shown). Similar baseline
migration, which was routinely 5–10% in our Transwell migration
assays (Figs. 1–5), was detectable for TCR
tgCD152
+/+ T cells and
TCR
tgCD152
2/2 T cells. Under these conditions, no migration
towards the CCR5 ligand CCL4 was seen in either population
(data not shown). In contrast, TCR
tgCD152
+/+ T cells migrated 2-
fold better in response to CXCL12 than did TCR
tgCD152
2/2 T
cells (Fig. 1A). Similarly, migration towards the CCR7 ligand
CCL19 was diminished by 70% in TCR
tgCD152
2/2 T cells
compared with TCR
tgCD152
+/+ cells.
To examine a role for CD152 in the contribution to the
migratory properties of pro-inflammatory T lymphocytes upon
primary stimulation, CD152
2/2 and CD152
+/+ TCR
tg
CD4
+CD62L
+ T lymphocytes were stimulated with antigen under
Th1 conditions and migration was evaluated in Transwell
chemotaxis assays on day 5 (data not shown) or day 6 after
stimulation (Fig. 1B); both assays gave similar results. Cells capable
of receiving a CD152 signal showed a significantly higher
migratory response toward the inflammatory chemokine CCL4
(Fig. 1B). In contrast, for the mainly homeostatic chemokines
CXCL12 and CCL19, no significant difference in migration was
observed when comparing monoclonal CD4 cells from
TCR
tgCD152
+/+ and TCR
tgCD152
2/2 mice.
CD152 functions are more pronounced upon activation of
antigen-experienced T cells than upon primary stimulation of
naı ¨ve T cells [27]. Therefore, we inactivated CD152 on antigen-
experienced Th1 cells by adding neutralizing anti-CD152 Fab
fragments to Th1 cells during primary stimulation and recall
response, and monitored migration on day 6 of recall response
(Fig. 1C). Polarization of primary Th1 cells resulted in .98% pure
effector populations, as confirmed by a CD44
high IFN-c
+ IL-4
2
phenotype (data not shown). Following recall responses of antigen-
experienced Th1 cells, cells that received a CD152 signal migrated
two-fold better towards CCL4 than Th1 cells that were activated
under a serological blockade of CD152 (Fig. 1C). Similarly,
blockade of CD152 by the addition of anti-CD152 Fab fragments
also resulted in reduced frequencies of cells migrating towards
CXCL12. To substantiate a role for CD152 in mediating the
migratory capacity of antigen-experienced T lymphocytes, we
used T cells from CD152
2/2 and CD152
+/+ mice. On day 4 after
a polyclonally induced recall response of splenocytes with anti-
CD3 and APCs, substantially more CD152
+/+ T cells migrated
compared with CD152
2/2 T cells (Fig. 1D): wild-type cells
migrated three- and two-times better than CD152
2/2cells toward
CCL4 and CXCL12, respectively. Intriguingly, using 10 mg/ml
instead of 1 mg/ml OVA during stimulation enhanced the
migration for TCR
tg CD152
+/+ T cells by 2-fold (Fig. 1E). In
contrast, CD152
2/2 T cells did not migrate significantly better
with higher peptide concentrations (Fig. 1E). Thus, the enhanced
migration of CD152
+/+ T cells towards CCL4 and CXCL12 was
dependent on the concentration of antigen during TCR
stimulation (duration and strength of signal). Interestingly, this
chemotaxis enhancing property was specific to CCL4 and
CXCL12, because no difference in migration towards CXCL9
occurred, even when high OVA concentrations were used for
stimulation. Migration towards CCL19 was slightly enhanced by
altering the signaling strength during stimulation, when Th1 cells
received a CD152 signal (Fig. 1E). Most strikingly, CD152
+/+ but
not CD152
2/2 antigen-experienced Th1 cells migrated to the
homeostatic chemokine CCL19.
In summary, the presence of functional CD152 enhanced the
chemotaxis of T cells, especially that of repeatedly activated Th1
cells.
CD152 enhances chemokine-driven transendothelial
migration
Recruitment of lymphocytes to the site of infection involves a
sequential, multi-step process leading to the active transmigration of
lymphocytes across the blood vasculature endothelium [28]. As
part of the process, lymphocytes migrate through endothelial cell
junctions, a step referred to as diapedesis. Using mlEND
endothelial cells grown confluently on a membrane (Fig. 2 inset),
transmigration of Th1 cells towards CCL4, CXCL12 and CCL19
across an endothelial layer was compared to transmigration across
a membrane only (Fig. 2). Migration of CD152
+/+ Th1 cells
towards indicated chemokine gradients of CCL4, CXCL12 and
CCL19 was enhanced at least two-fold as compared with
CD152
2/2 Th1 cells, no matter whether transmigration was
performed across a membrane only or across an endothelial layer.
Thus, we conclude that CD152 engagement enhances transen-
dothelial migration of T cells (Fig. 2).
CD152-induced migration of pre-activated Th1 cells
depends on Gai signaling and is independent of IFN-c
Chemokine receptors are known to signal through G proteins
[29]. By blocking Gai-linked chemokine receptor signaling with
CD152 Promotes Migration
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that of background migration (Fig. 2). Thus, CD152-enhanced
migration of T cells completely depends on Gai signal transduction.
To control for the possibility that increased IFN-c levels of
CD152
2/2 T cell populations contributed to the reduced migration
[11,30], the IFN-c-production was examined during in vitro culture.
Figure 1. CD152 enhances chemotaxis of Th1 cells. (A) Migration of unpolarized T cells. Recall response of CD4
+ OVA-specific TCR
tg T cells from
CD152
2/2 or CD152
+/+ mice was induced by adding 1 mg/ml OVA323–339 and T cell-depleted APCs. On day 6 of recall response cells were analyzed in
chemotaxis assays. Bars indicate migrated CD4
+ cells as percentage of input cells. (B) Migration of CD152
2/2 and CD152
+/+ T cells in primary
stimulation: CD4
+ OVA-specific TCR
tg T cells were stimulated with 1 mg/ml OVA323–339 and T cell-depleted APCs. On day 6 of primary stimulation cells
were analyzed in chemotaxis assays. Bars show the chemotactic index of CD4
+ cells. (C) Specific migration of antigen-specific stimulated Th1 cells in a
recall response: Primary stimulation and recall response of CD4
+CD62L
+ OVA-specific TCR
tg T cells were performed under Th1 conditions with 1 mg/ml
OVA-peptide in the presence of 200 mg/ml neutralizing anti-CD152 Fab fragments or hamster control Fab fragments. Cells were examined in
chemotaxis assay on day 6 of recall response. (D) Chemotactic index of a polyclonally induced recall response of CD152
2/2 or CD152
+/+ Th1 cells:
Primary stimulation and recall response of splenocytes from CD152
2/2 and CD152
+/+ mice were induced polyclonally (as described in Material and
Methods) and CD4
+ cells were used for chemotaxis assays on day 4 of recall response. (E) Migration of CD152
2/2 and CD152
+/+ Th1 cells in a recall
response is dose dependent: Primary stimulation and recall response of CD4
+ cells from TCR
tg CD152
2/2 and CD152
+/+ mice were induced antigen-
specifically using Th1 conditions with indicated amounts of OVA-peptide and cells were analyzed on day 6 of recall response in chemotaxis assays. All
data shown represent one out of 3–4 similar experiments.
doi:10.1371/journal.pone.0005702.g001
CD152 Promotes Migration
PLoS ONE | www.plosone.org 3 May 2009 | Volume 4 | Issue 5 | e5702Similar IFN-c-production was detected in TCR
tgCD152
2/2 and
TCR
tgCD152
+/+ CD4
+ T cells under Th1 conditions and with
strongantigenicstimulus(10 mg/mlOVA-peptide;datanotshown).
Furthermore we inhibited IFN-c by adding neutralizing anti-IFN-c
to the cultures during the antigenic recall response. Adding anti-
IFN-c led to an overall reduction in migration, however, the
reduced migration of TCR
tgCD152
2/2 Th1 cells could not be
reversed by blocking IFN-c (Fig. 3). Furthermore, addition of
exogenous IFN-c to the cultures did not reduce migration of
CD152
+/+ Th1 cells, indicating that CD152-modulated migration
of Th1 cells was not due to effects of different IFN-c concentrations
between cultures of TCR
tgCD152
2/2 Th1 cells and
TCR
tgCD152
+/+ Th1 cells.
CD152 engagement induces chemokine responsiveness
of recently activated T lymphocytes
CD152 exerts its main function during its peak expression in a
T cell response, which is typically 48 h following activation
[11,16]. To monitor CD152-mediated effects on T cell migration,
a recall response of Th1 cells was induced for 48 h with congenic
APCs and OVA. Additionally, antibody-coupled microspheres
were used to cross-link CD152 in combination with CD3 and
CD28 coligation. The stimulation with anti-CD3/anti-CD28-
coupled microspheres allowed for direct crosslinking of CD152
and also kept the CD28-signal constant in all populations. On day
3 of activation, migration of activated CD152-engaged Th1 cells
towards CXCL12 and CCL19 was considerably enhanced
compared with Th1 cells engaged only with CD3 and CD28
(Fig. 4A). Strikingly, 4-times more Th1 cells migrated towards
CCL4 after stimulation with anti-CD3/anti-CD28/anti-CD152
compared with anti-CD3/anti-CD28-stimulated T cells. Thus,
CD152 engagement in concordance with CD3 and CD28 of Th1
cells triggered chemokine responsiveness in the absence of
additional signals provided by APCs.
To confirm that enhanced migration of Th1 cells is regulated by
CD152 and is not merely the result of an early differentiation
event, we retrovirally transduced CD152
2/2 cells during in vitro
stimulation with the cDNA of full length CD152 (pMSCV-
CD152). Upon a recall response, retroviral transduction with
pMSCV-CD152, but not with the control vector, restored
migration towards CCL4 in CD152
2/2 cells (Fig. 4B). Thus,
CD152 expression mediates enhanced migration even in highly
activated T cells and the detected lack of migration of CD152
2/2
T cells is due to their lack of CD152 and not to developmental
alterations.
Next, we determined whether the CD152-controlled migration
towards the inflammatory chemokine CCL4 and the homoeostatic
chemokine CCL19 reflects heterogeneity of the T cell population.
When migration towards a single chemokine gradient of CCL4 or
CCL19 was tested, TCR
tgCD152
+/+ Th1 cells showed enhanced
migration compared with TCR
tgCD152
2/2 Th1 cells after
antigen-specific recall responses (Fig. 4C). Migration to a
combined chemokine gradient of CCL4 and CCL19 was similar
to migration towards a single CCL4 gradient, suggesting that the
same cell population responds upon CD152-signaling towards
CCL4 and CCL19.
Figure 2. Only CD152
+/+ but not CD152
2/2 cells show efficient
transendothelial migration. Primary stimulation and recall response
of CD4
+ OVA-specific TCR
tg T cells from CD152
2/2 and CD152
+/+ mice
were performed using Th1 conditions with 10 mg/ml OVA-peptide and
T cell-depleted APCs. On day 6 of recall response migration of CD4
+
cells through membranes coated with or without endothelial mono-
layer was analyzed after 90 min. incubation at 37uC in Transwell
chemotaxis assay. CD152 mediated migration of Th1 cells is G-Protein
dependent: CD4
+ OVA-specific TCR
tg CD152
2/2 and CD152
+/+ Th1 cells
were incubated for 2 hours at 37uC in the presence of 100 ng/ml
Pertussis toxin prior to examination in chemotaxis assay. (Inset)
Endothelial cells (mlEND) were grown to a confluent monolayer for
48 h on Transwell membranes and confluency was controlled by
microscopy. Shown data represent one out of 2 similar experiments.
doi:10.1371/journal.pone.0005702.g002
Figure 3. CD152-enhanced migration is IFNc independent. CD4
+
OVA-specific TCR
tg splenocytes from CD152
2/2 and CD152
+/+ were
stimulated under Th1 conditions (as described in Fig. 2) in the presence
of 20 ng/ml recombinant IFN-c or 10 mg/ml blocking anti-IFN-c -
antibodies. On day 6 after inducing a recall response cells were
analyzed for migration towards CCL4 in chemotaxis assays. The data
represent one out of 3 similar experiments.
doi:10.1371/journal.pone.0005702.g003
CD152 Promotes Migration
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cells stimulated by DCs
CD152 is not expressed on the surface of resting T cells and is
difficult to detect even after stimulation of T cells [18,31,32]. In
order to analyze CD152 expression on individual T cells activated
by different APCs we stimulated naı ¨ve OVA-specific CD4
+ T
lymphocytes with the peptide OVA323–339 loaded on either
activated B lymphocytes or DCs. To unambiguously identify T
cells expressing surface CD152, we used an enhanced staining
technique [33] based on CD152-specific immunofluorescent
liposomes, which increased the detection sensitivity at least
1000-fold [11,16]. Employing this method, expression of surface
CD152 was evaluated at various time points after T cell activation
(Fig. 5A, C). B cells and DCs stimulated T cells equally well as
determined by the induction of similar T cell proliferation rates of
85–86% (Fig. 5B) on day 3 after onset of stimulation. Specific
surface expression of CD152 was detected with low frequencies on
day 1 in primary T cell cultures activated with either activated B
cells or DCs. Following primary stimulation, CD152 expression
increased and peaked after 48 h. Thereafter, the percentage of
surface CD152-expressing cells declined in both cultures and these
cells were infrequent (,3%) after 3 days of stimulation. At the
peak of surface CD152 expression, T cell populations stimulated
by DCs displayed enhanced expression of surface CD152.
Whereas more than 23% of the T cells stimulated by DCs
expressed surface CD152, only ,3% of the T cells displayed
CD152 on their surface 48 h after stimulation with activated B
cells (Fig. 5A, C). The number of surface CD152-expressing cells
could not be attributed to contaminating Th2 cells, as no IL-4
producers were present in the cultures (data not shown). Thus,
mainly T cells stimulated by DCs are able to express surface
CD152, showing that the activation history and activating cell type
(DC versus B cell) regulate CD152 expression on T cells.
Next, we asked whether the differential potential of DCs versus
activated B cells to induce CD152 on T cells correlated with a
differential potential to license T cells for chemotaxis. Correlating
with the induction potential of CD152 on T cells, T cells
stimulated by DCs migrated significantly better in response to
CCL4 or CXCL12 than did T cells activated by B cells (Fig. 5D).
Thus, the data suggest that chemokine-driven migration of T cells
is controlled by mature DCs and correlates tightly with the up-
regulation of surface CD152 on T cells.
CD152 induces expression of chemokine receptors CCR5
and CCR7
Many reports show that CD152 down-regulates expression of
effector molecules such as IL-2 and cyclin-dependent kinases
[9,34]. We have shown recently that CD152 can indeed up-
regulate the expression and activate molecules such as Bcl-2,
pFKHRL1, and PI3’K [11]. To determine the effects of CD152
on the expression of chemokine receptors, cells from CD152
2/2
and CD152
+/+ mice were used. After polyclonal stimulation of
splenocytes from CD152
2/2 and CD152
+/+ mice with anti-CD3
and induction of recall response with syngeneic APCs and anti-
CD3, we detected no difference in CXCR4 expression (Fig. 6A),
but we found enhanced expression of CCR7 by CD152
+/+ cells
compared with CD152
2/2 cells (Fig. 6B). To further elucidate the
role of CD152 in the induction of CCR5, splenocytes of CD152
2/2
and CD152
+/+ mice were activated with anti-CD3 under Th1
polarizing conditions, and upon recall response, analyzed for CCR5
Figure 4. CD152-signaling mediates migration of recently activated Th1 cells. (A) CD4
+CD62L
+ TCR
tg T cells were stimulated with 1 mg/ml
OVA peptide and T cell-depleted APCs under Th1 conditions. Recall response of Th1 cells was induced by platebound anti-CD3/anti-CD28 for
48 hours. Cells were washed, incubated with microspheres coated with anti-CD3, anti-CD28 and anti-CD152 (0.15 mg/ml, 0.4 mg/ml, 4.5 mg/ml
respectively) or anti-CD3, anti-CD28 and hamIgG for additional 24 hours and examined in chemotaxis assay. (B) Restored specific migration of
CD152
2/2 Th1 cells by CD152 expression. CD152
2/2 splenocytes were activated with 2 mg/ml anti-CD3 under Th1 conditions and on day 2 were
retrovirally transduced with cDNA of full length CD152 (pMSCV-CD152) or with empty vector pMSCV. Chemotactic capacity of transduced CD4
+ cells
was determined in chemotaxis assays. (C) Migration towards CCL19 plus CCL4. CD4
+ TCR
tg T cells from CD152
+/+ and CD152
2/2 mice were stimulated
under Th1 conditions as described in figure 2. On day 6 of recall response viable cells were analyzed in chemotaxis assays for migration capacity
towards CCL4 and CCL19 alone or in combination. One out of at least 3 experiments with similar results is shown.
doi:10.1371/journal.pone.0005702.g004
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+ cells is up-regulated by
stimulation with DCs. Nave CD4
+CD62L
+ TCR
tg T cells were stimulated with 1 mg/ml OVA-peptide presented by matured DCs or by LPS-activated B
cells. After 48 hours surface expression of CD152 was detected by liposome staining technique and subsequent FACS analysis. Left panels show
CD152 staining, right panels show blocking controls. Numbers indicate the percentage of CD152
+ CD4
+ based on total CD4
+ cells. (B) Equal
proliferation of T cells stimulated with activated B cells or matured DCs. Nave CD4
+CD62L
+ TCR
tg T cells were labeled with CFSE and antigen-
specifically stimulated with activated B cells or matured DCs. Proliferation of T cells was determined by flow cytometry 48 hours (filled curve) and
72 hours later (black line). T cells cultured with different APCs but without antigenic stimulation are shown as heavy grey line. Numbers indicate the
percentage of divided T cells 72 hours after stimulation relating to unstimulated controls (after 48 h 48% of Dc-stimulated T cells and 46% of Bc-
stimulated T cells proliferated). (C) Kinetics of CD152 surface expression on CD4
+ T cells. Indicated time after onset of stimulation cells cultured as
described in 5A were stained with liposome staining technique for CD152. Percentages of surface expressing CD152 cells of total CD4
+ cells are
shown. (D) Chemotactic index of Th1 cells stimulated with different APCs. CD4
+CD62L
+ TCR
tg T cells were stimulated under Th1 conditions with 1 mg/
ml OVA peptide presented by activated B-cells or bone marrow derived DCs. On day 6 of primary stimulation, CD4
+ cells were analyzed for migration
capacity in chemotaxis assay. All data show representative data from at least two experiments.
doi:10.1371/journal.pone.0005702.g005
Figure 6. CD152 mediates up-regulation of chemokine receptors CCR5 and CCR7. Recall response of splenocytes from CD152
+/+ and
CD152
2/2 mice was induced polyclonally under Th1 conditions. On day 3 of recall response, cells were stained for surface markers and analyzed by
flow cytometry. The histograms indicate surface expression on CD4
+ lymphocytes of (A) CXCR4, (B) CCR7 and (C) CCR5; (M1: 48% CD152
+/+; 29%
CD152
2/2). (D) After performing recall response of splenocytes from CD152
+/+ mice with microspheres (as described in Fig. 4A) CCR5 was detected
on CD4
+ cells. Representative results from one out of 3–5 experiments are shown.
doi:10.1371/journal.pone.0005702.g006
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+/+ than CD152
2/2
CD4 T cells expressed CCR5 on their cell surface (Fig. 6C). In
addition, agonistic signaling of CD152 in CD152
+/+ T lymphocytes
using anti-CD3/anti-CD28/anti-CD152 cross-linking under Th1
conditions up-regulated CCR5 as compared to T cell activation
with only anti-CD3/anti-CD28 cross-linking (Fig. 6D). Thus,
CD152 regulates expression of the chemokine receptors CCR5
and CCR7 correlating with the observed CD152-enhanced
migration to the corresponding ligands CCL4 and CCL19.
Differential migration pattern of CD152
+/+ and CD152
2/2
Th1 cells in vivo
To test the in vivo significance of the enhanced in vitro migration
towards inflammatory and lymphoid chemokines due to CD152
signaling, we analyzed the in vivo homing capacity of CD152
+/+
and CD152
2/2 TCR
tg Th1 cells. Recipient mice were either
injected i.v. with radioactively labeled CD152
+/+ TCR
tg Th1 or
CD152
2/2 TCR
tgTh1 cells. 24 h after cell transfer, mice were
injected s.c. into one footpad with OVA-peptide in IFA and in a
control footpad with PBS in IFA only. 24 h later, radioactivity in
different organs, the inflamed and accordingly control footpad was
measured (Fig. 7A). Both transferred cell populations accumulated
with no difference in non-inflamed organs (including gut, skin,
lung, spleen, liver, rest of the body). Strikingly, CD152
+/+ Th1
cells migrated enhanced into resting and inflammation draining
lymph nodes compared with CD152
2/2 Th1 cells (Fig. 7A).
Importantly, CD152
+/+ Th1 cells migrate 2-fold better into the
site of inflammation (footpad) than did CD152
2/2 Th1 cells
(Fig. 7B). In independent experiments testing migration in the
absence of inflammation, CD152
+/+ Th1 cells also homed better
than their CD152
2/2 counterparts into lymph nodes
(p|=|0.0006; data not shown). The detected differences in
migration were not due to differences in polarization or activation
status of CD152
2/2 versus CD152
+/+ T cells since both subsets
expressed similar levels of the activation markers CD69, CD44,
CD25, CD62L, had an identical capacity to secrete IFN-c before
stimulation (Fig. 7C, upper panel) and on day 5 after induction of
recall response (Fig. 7C, lower panel) and showed no IL4-, IL10-
or IL17-producing T cells at the time point of analysis in
chemotaxis assays (data not shown). Consistent with their in vitro
migration to inflammation (CCL4, CXCL12) and lymph node
expressed chemokines (CCL19, CXCL12) CD152 competent T
cells are licensed for migration into both, sites of acute
inflammation and lymph nodes.
Discussion
Our results show that CD152 expression and signaling in T cells
is a major control point for their migration both in vitro and in vivo.
The heterogeneity of CD152 expression in individual primary T
cells stimulated by different APCs has not been analyzed
previously and our study reveals that T cells stimulated by
different APCs also differ in CD152-mediated enhanced in vitro
Figure 7. Th1 cell homing to the site of inflammation and lymph nodes is enhanced by CD152. (A) Distribution of TCR
tg CD152
2/2 and
CD152
+/+ Th1 cells 48 hours after transfer. In vitro induced Th1 cells from a recall response were radioactively labeled and injected i.v. (5610
6 cells per
mouse). After 24 hours OVA-peptide (250 ng) in IFA was administered s.c. into one footpad (DTH); PBS/IFA-injection in the other footpad served as
control. Different organs were analyzed after 48 hours for radioactivity. Recovered radioactivity in organs was calculated as percentage of total
amount of radioactivity per mouse (7 mice per group). (LN: mesenteric and axillary lymph nodes; drLN: draining (popliteal and inguinal) lymph nodes;
PBL: peripheral blood lymphocytes). Results from one out of two similar experiments are shown. (B) Specific migration of transferred CD152
2/2 and
CD152
+/+ Th1 cells to the site of inflammation. Radioactively labeled CD152
2/2 and CD152
+/+ Th1 cells were transferred into mice and DTH was
induced in footpads as described in 7A. Shown is the antigen-dependent accumulation of Th1 cells to the site of inflammation indicating the ratio of
recovered radioactivity in the inflamed footpad versus the PBS injected footpad. (C) Similar expression of activation induced markers and similar
amount of IFN-c-producers. TCR
tg CD152
2/2 and CD152
+/+ CD4
+ T cells were either left unstimulated or were in vitro stimulated under Th1 conditions
and a recall response was performed. Unstimulated cells were stained on day 3 (upper panel) and stimulated cells on day 5 of recall response for
activation induced molecules (lower panel). Intracellular staining for IFN-c of fixed cells was performed on day 3 of recall response after restimulation
with PMA/Ionomycin for 6 hours; Brefeldin A was added for the last 2 hours of incubation. One out of two similar experiments is shown.
doi:10.1371/journal.pone.0005702.g007
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surface CD152 and as a consequence migrated in response to
CCL4 and CXCL12. Importantly, CD152 signals also enhanced
Th1 cell migration into lymph nodes and a site of cutaneous
inflammation in a short term in vivo homing assay. Thus, CD152
ligation determines the positioning of inflammatory T cells at the
site of inflammation in vivo.
Expression of CD152 on the surface of primary T cells is difficult
to detect using conventional cytometric and microscopic techniques
[16,18,35,36]. Consequently, most studies on CD152 expression
have used intracellular staining methods. In contrast, the sensitive
liposome-based staining technique used in this study allowed the
detection of as few as 100 to 200 surface molecules per cell [37].
Using this method, we showed that the type of activating APC
determines the frequency of surface CD152 expressing T cells.
Interestingly, mature DCs, but not activated B cells, were potent in
up-regulating surface CD152 on T cells. The fact that differentially
activated (i.e. DC vs. activated B cell) T cells differentially express
CD152 during an immune response raised the possibility that
surface CD152
+ and surface CD152
no/low T cells could also be
heterogeneous in their migratory potentials. Indeed, many more
DC-activated T cells expressed surface CD152 and were able to
chemotax than were B-cell activated T cells (Fig. 5). Thus, different
classes of APC induce distinct T cell migration patterns via the
differential induction of CD152 on T cells.
CD152 and CD28 share common B7 ligands. However, B7
expression is not limiting on APCs during an optimal immune
response, enabling saturated engagement of both CD28 and
CD152 [14], making a simple competition of CD152 over CD28
unlikely and dispensable in our experiments. Additionally, there is
accumulating evidence that CD152 directly modulates proximal
TCR signaling [38]. It is therefore unlikely that enhanced CD28
signaling occurs during serological or genetic blockade of CD152.
Therefore, we conclude that CD152-enhanced migration of Th
cells is not simply a result of impaired CD28 signaling.
Most studies showed that CD152 signaling down-regulates
expression of molecules and, ultimately, the function of T cells. In
addition, CD152 signaling can up-regulate the expression and
activation of molecules such as TGFb, Bcl-2, pFKHRL1, LFA1,
and PI3’K [11,39,40]. Functionally, this means that cells
expressing CD152 on the cell surface and receiving a CD152
signal are resistant against activation-induced cell death [11].
Additionally, CD152 signals in activated T cells lead to reduced
adhesion and increased motility that result in shortened T cell-
APC interactions within lymph nodes [38,41]. This finding was
interpreted as a mechanism to down-regulate the immune
response [42]. Thus, our data add an important new piece to
the puzzle by showing that CD152 signals license T cells for
chemotaxis and migration into lymph nodes and inflammatory
sites. In conclusion, CD152-signaling does not simply silence T
cells, but rather enables them to actively contribute to the immune
response by enhancing effector T cell migration in vivo.
We have now demonstrated that CD152 signaling enhances the
cell surface expression of CCR5 and CCR7 on T cells. It is likely
that up-regulation of CCR5 and CCR7 supports the CD152-
mediated enhanced migration towards of the cognate ligands
CCL4 and CCL19, respectively. However, this may not be the
only mechanism. For example, we were not able to detect CXCR4
up-regulation in response to CD152 signaling, even though we
detected enhanced migration to its ligand CXCL12 (Fig. 1A–E).
Chemotaxis is not always accompanied by enhanced chemokine
receptor expression on leukocytes because factors that influence
chemokine receptor signaling additionally control the migratory
capacity in response to chemokines [43–46]. Thus, CD152 could
regulate T cell chemotaxis alternatively or additionally to the
induction of chemokine receptors on T cells by controlling
downstream signaling events.
Our study is the first report demonstrating that CD152 ligation
as well as genetic or serological ablation of CD152 signaling affects
chemotaxis of primary T cells. At first view, our data seems to be
inconsistent with the observation that CD152
2/2 mice show
dramatic lymphocyte infiltration of tissues [14,28,35,47]. Howev-
er, in these studies a massive expansion of activated lymphocytes is
seen; and the cells might just overflow throughout the body in
shortage of space. Therefore, it is likely that lymphocytic
infiltration of tissues is not only a consequence of directed
migration. Alternatively, migration of the expanded cell popula-
tions into tissues might be fairly random, but as CD152
2/2 cells
express CCR7 only at low frequencies (Fig. 6B), and CCR7
expression has been shown recently to be a prerequisite for T cells
to exit extralymphoid tissues [48,49], they could be retained in
peripheral tissues.
In this study, we have shown that enhanced avidity of the TCR
determines migration of CD152
+/+ T cells along chemokine
gradients. This suggests that cells receiving the most optimal
signals during stimulation show enhanced CD152 expression and
are licensed to migrate. These data are consistent with work of
Allison and colleagues, showing that T cells receiving a strong
signal up-regulate CD152 [15,18]. However, our results demon-
strate that CD152 expressing T cells are not silenced by CD152-
signaling but, on the contrary, are directed for migration, thereby
driving and preserving the immune response.
Taking into account that CD152 induces resistance against
activation-induced cell death, together with our new results that
CD152 enhances chemotaxis of already activated, effector-
cytokine producing T cells, we hypothesize that CD152 surface
expression and signaling marks the ‘‘fittest’’ T cells out of a
heterogeneous population of stimulated T cells [50]. Depending
on the environment, the CD152-marked cells would home to
secondary lymphatic organs or to the site of inflammation,
probably depending on the stimulation history and the quality of
the chemotactic gradient [51]. These cells will be allowed, via
CD152 signaling to drive the immune response to fight pathogens
immediately and to drive progressive T cell differentiation of TCM
cells. Thus, CD152 might actively determine the fate of an effector
T cell.
Importantly, consistent with our data showing that CD152 up-
regulates expression and function of CCR7, a receptor crucial for
entry of resting T cells and Th1 cells from the bloodstream into
lymph nodes [24,26,52], we found that migration of T cells into
lymph nodes was enhanced by CD152 (Fig. 7A). Moreover, we
found that CD152 signals promoted accumulation of Th1 cells at a
site of cutaneous inflammation (Fig. 7B), which was most likely the
consequence of the CD152-enhanced responsiveness to CCL4 and
CXCL12 (Fig. 1E, 2) as both ligands are widely associated with
inflammation [22,23]. However, CCR7 ligands can also be up-
regulated in chronic inflammation [53,54] and others have shown
a role for CCR7 ligands in T cell migration into inflamed non-
lymphoid tissues [55]. Consequently, it is possible that CD152-
regulated CCR7 expression contributes to effector T cell
migration into both lymphoid organs and inflamed tissues.
Our data suggest that upon activation, T cells will not migrate
efficiently into lymph nodes and inflamed tissues unless they up-
regulate surface CD152. The migratory properties of the cell
population are important to mount an adaptive immune response
in the periphery. Thus, CD152 might be one master switch to
determine that lymphocytes are in the right time at the right
place.
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Mice
Transgenic (tg) mice for OVA-specific TCR
tg/tg on BALB/c
background (Do11.10, gift from Dennis Y. Loh, Washington
University School of Medicine, St. Louis, MO) or C57/B6
background (OTII), CD152 knock-out mice on C57/B6 back-
ground (gift from James P. Allison, University of California at
Berkeley, CA). All mice were bred under specific pathogen-free
conditions at the Bundesinstitut fu ¨r Risikobewertung (Berlin) and
were used at the age of 5 to 10 weeks except for non-transgenic
CD152
2/2 mice, which were used at the age of 3 weeks. Animal
studies were reviewed and approved by Landesamt fu ¨r Gesundheit
und Soziales, Berlin (G0075/02).
Antibodies, cytokines and reagents
The following antibodies were used: anti-CD152 (UC10-4F10-11),
anti-CD25 (7D4), anti-CD69 (H1.2F3), anti-IL4 (11B11), anti-CCR5
(C34-3448), anti-CXCR4 (2B11/CXCR4), ratIgG1 (R3-34), ha-
mIgG2 (KLH, HA4/8), ratIgG2c, ratIgG2b (A95-1) (all from BD
Biosciences), anti-CCR7 (4B12, eBioscience) ratIgG2a (eBioscience)
coupled to FITC, PE or Cy5-conjugates. Anti-CD28 (37.51), anti-
CD3 (145-2C11), anti-IL4 (11B11), anti-CD4 (GK-1.5/4), anti-
CD62L (MEL-14), anti-CD44 (IM7), anti-TCR
tg (KJ1-26.1), anti-
IFN-c (AN18.17.24), anti-CD11c (N418), anti-CD152 (UC10-4F10-
11) and Syrian hamster control antibody (560-31.1B9; kindly
provided by J.P. Allison) were purified from hybridoma supernatants.
Anti-CD152 Fab fragments were prepared with the Immunopure
Fab preparation kit (Pierce) and used at 200 mg/ml. Recombinant
chemokines and IL-12 were from R&D Systems, pertussis toxin from
Sigma; magnetic microbeads (anti-CD4, anti-CD19, anti-CD43,
anti-CD62L, anti-CD90, anti-FITC multisort) were from Miltenyi-
Biotech; and sulfate polystyrene latex microspheres of 5 mm60.1 mm
mean diameters from Interfacial Dynamics.
Cell isolation and stimulation
Isolation of naı ¨ve CD62L
highCD4
+ T cells was performed using
magnetic cell separation (MACS
TM) to a purity greater than 98%.
Isolated TCR
tg cells were stimulated with 1 or 10 mg/ml OVA323–
339 peptide (provided by Schneider-Mergener, Charite ´) and T cell-
depleted splenocytes as APCs. On day 6 after onset of stimulation,
recall response was performed by adding freshly isolated APCs and
OVA-peptide to density-gradient-purified cells. CD152
2/2 or
CD152
+/+ TCR
wt splenocytes were stimulated with 1.5 mg/ml
ConA and recall response was induced on day 5 with 2 mg/ml anti-
CD3 and CD90
2 APCs from syngeneic C57/B6 mice. CD43
2 B
cells were activated with 20 mg/ml LPS for 24 hours. DCs were
generated from bone marrow of syngeneic mice by culturing for 8
days with 10% GM-CSF and subsequent maturation for 24 hours
with TNFa (10 ng/ml). For Th1 polarization recombinant IL-12
(10 ng/ml) and anti-IL-4 (6 mg/ml) were added to the cultures.
Crosslinking of CD152 on CD4 cells was performed using latex
microspheres coated with antibodies against CD3 (0.15 mg/ml),
CD28 (0.4 mg/ml), CD152 or a hamster control antibody (N418,
4.5 mg/ml) as described [16,32]. CD4 T cells (1610
6/ml) were
stimulated at a ratio of one bead per cell with antibody-coupled
microspheres. Cell cycle progression was measured by labeling of T
cells with CFSE (5 mM in PBS, Molecular Probes) for 5 min at
room temperature. The reaction was stopped by washing and
resuspending the cells in RPMI-1640 medium.
Flowcytometric analysis of CD152 surface expression
Surface expression of CD152 was detected using magneto-
fluorescent liposomes [16,33]. T cells were incubated with 1 mg/
ml hamster CD152 antibody of for 15 min at 4uC. Cells were
washed and incubated with Cy5 dye-filled liposomes, conjugated
to hamster Fab fragments, for 30 min at 4uC. Unbound liposomes
were removed by washing. The specificity of CD152 staining was
controlled by isotype control antibody conjugated with Cy5-filled
liposomes as well as by incubation of cells with Cy5-filled
liposomes only.
Retroviral transduction
293T fibroblasts were transfected with calciumphosphate-pre-
cipitated pECO, pCGP, pMSCV-GFP (empty vector) or pMSCV-
GFP-CD152 (containing full length CD152 cDNA) respectively.
After 4 hours medium was exchanged and fibroblasts were cultured
for additional 48 hours in DMEM containing 10% FCS, 2 mM
glutamine and 50 mM 2-mercaptoethanol. CD152
2/2 splenocytes,
activated with 2 mg/ml anti-CD3 using Th1 conditions for 1–2
days, were resuspended in virus supernatant and retrovirally
transduced by centrifugation for 90 minutes at 25uC. Cells were
resuspended in conditioned medium, recall response was performed
on day 4 and cells were analyzed in chemotaxis assays 3 days later.
Chemotaxis assay
Th1 cells were collected on day 4–6 of recall response. After
density centrifugation on Histopaque 1083 (Sigma-Aldrich),
chemotaxis assays were performed using 5-mm pore polycarbonate
Transwell filters (Corning Costar). 5610
5 cells in 100 ml assay
medium were added on fibronectin-coated filters (10 mg/ml,
Invitrogen), chemokine dilutions (10 nM CCL4, 10 nM CCL19,
20 nM CXCL12, 100 nMCXCL9)or medium were given to lower
chambers. For transmigration through endothelium, 5610
4
mlEND1 cells (gift from Prof. Dr. Rupert Hallmann, University
Hospital,Lund)inmediumwereseededonfibronectin-coated filters
and incubated for 48 hours before adding Th1 cells. Migrated cells
wererecovered after 90 min of incubation at 37uC and frequency of
migrated cells was determined by staining with anti-CD4 (L3T4,
BD Biosciences) and comparing numbers to a fixed amount of
fluorescent beads (Fluoresbrite Microparticles 20 mm, Polysciences
Inc.) by flow cytometry [52]. All determinations were performed in
triplicate. Chemotactic index indicates the ratio of cells migrated to
chemokine versus medium. Confluence of the endothelial mono-
layer was checked by microscopic analysis. To do so, cells were
washed in PBS, fixed with paraformaldehyde, stained with
GIEMSA-solution for 30 min. and dried over night. Membranes
with cells were removed from the inserts and embedded in Entellan.
Migration of lymphocytes in vivo
In vitro cultured Th1 cells from OVA-TCR
tg CD152
2/2 and
CD152
+/+ were collected on day 5 of recall response. Cells were
radioactively labeled with 20 mCi/ml sodium (
51Cr) chromate
(Hartmann Analytic) for 1 hour at 37uC. After washing and dead
cell removal, 5610
6 cells in 200 ml HBSS per mouse were injected
i.v. into tail veins in seven C57/B6 mice per group. 24 hours later,
delayed type hypersensitivity (DTH) response was initiated by
administration of OVA-peptide (250 ng) in IFA (Pierce) s.c. into
one footpad. Injection of PBS/IFA in the other footpad served as
control. 48 hours after cell transfer mice were sacrificed and
organs were analyzed by Beckmann c-Counter for recovered
radioactivity. Radioactivity in different organs was calculated as
percentage of total amount of radioactivity per mouse.
Statistical Analysis
Statistical analysis was performed using the two-tailed unpaired
Student’s t-Test (Figure 1–5) or Mann-Whitney Test (Figure 7A,
CD152 Promotes Migration
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significantly different.
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